Stayble Therapeutics AB (SE:STABL)
:STABL
Want to see SE:STABL full AI Analyst Report?
STABL Stock Chart & Stats
kr0.24
kr0.07(17.59%)
At close: 4:00 PM EST
kr0.24
kr0.07(17.59%)
Day’s Range― - ―
52-Week Rangekr0.03 - kr0.57
Previous CloseN/A
Volume514.07K
Average Volume (3M)378.51K
Market Cap
kr2.92M
Enterprise Valuekr469.94K
Total Cash (Recent Filing)kr2.45M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,359,795
10 Day Avg. Volume398,578
30 Day Avg. Volume378,512
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtA near-zero debt load is a durable strength for a pre-revenue biotech: it reduces fixed financing obligations, preserves strategic flexibility for funding R&D or partnering, and lowers bankruptcy risk, allowing management to prioritize clinical milestones over debt servicing.
Improving Cash-burn TrendA materially reduced operating cash burn over multiple years reflects improving operational efficiency and tighter cost control, which can extend runway and reduce the pace and size of future financing needs, strengthening the company's ability to execute longer-term clinical plans.
Focused Lead Program And R&D StrategyA concentrated pipeline with a single lead candidate targeting a defined chronic pain indication supports disciplined capital allocation, clearer development milestones, and makes the company an attractive partner or acquisition target if clinical results validate the mechanism.
Bears Say
No Revenue (pre-commercial)Absence of product revenue is a fundamental long-term risk: the business remains fully dependent on external capital or partnerships to fund trials and operations, creating execution and financing risk until regulatory approval and commercial launch occur.
Eroding Equity And Asset BaseSustained losses that materially shrink equity and assets weaken balance-sheet resilience, limit borrowing capacity, and increase the likelihood of dilutive capital raises, undermining shareholder value and the company's ability to self-fund longer-term development.
Persistent Negative Cash Flow And FCFContinued negative operating and free cash flow means the company cannot self-sustain; this structural cash deficit necessitates recurrent external financing, heightening dilution risk and potentially delaying critical clinical or regulatory milestones if funding gaps arise.
STABL FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was kr0.03 and its highest was kr0.57 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is kr2.92M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Stayble Therapeutics AB’s earnings last quarter?
Currently, no data Available
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 64,359,795 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in SE:STABL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.